These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

508 related articles for article (PubMed ID: 27438833)

  • 1. A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints.
    Li Y; Li F; Jiang F; Lv X; Zhang R; Lu A; Zhang G
    Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27438833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-1/PD-L1 and immunotherapy for pancreatic cancer.
    Feng M; Xiong G; Cao Z; Yang G; Zheng S; Song X; You L; Zheng L; Zhang T; Zhao Y
    Cancer Lett; 2017 Oct; 407():57-65. PubMed ID: 28826722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-PD-1 and Anti-PD-L1 Monoclonal Antibodies in People Living with HIV and Cancer.
    Lurain K; Ramaswami R; Yarchoan R; Uldrick TS
    Curr HIV/AIDS Rep; 2020 Oct; 17(5):547-556. PubMed ID: 32827111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.
    Wang T; Wu X; Guo C; Zhang K; Xu J; Li Z; Jiang S
    J Med Chem; 2019 Feb; 62(4):1715-1730. PubMed ID: 30247903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From monoclonal antibodies to small molecules: the development of inhibitors targeting the PD-1/PD-L1 pathway.
    Zhan MM; Hu XQ; Liu XX; Ruan BF; Xu J; Liao C
    Drug Discov Today; 2016 Jun; 21(6):1027-36. PubMed ID: 27094104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations.
    Jiang Y; Chen M; Nie H; Yuan Y
    Hum Vaccin Immunother; 2019; 15(5):1111-1122. PubMed ID: 30888929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Research Progress Concerning Dual Blockade of Lymphocyte-Activation Gene 3 and Programmed Death-1/Programmed Death-1 Ligand-1 Blockade in Cancer Immunotherapy: Preclinical and Clinical Evidence of This Potentially More Effective Immunotherapy Strategy.
    Qi Y; Chen L; Liu Q; Kong X; Fang Y; Wang J
    Front Immunol; 2020; 11():563258. PubMed ID: 33488573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune Checkpoint PD-1/PD-L1: Is There Life Beyond Antibodies?
    Konstantinidou M; Zarganes-Tzitzikas T; Magiera-Mularz K; Holak TA; Dömling A
    Angew Chem Int Ed Engl; 2018 Apr; 57(18):4840-4848. PubMed ID: 29178534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.
    Sun X; Roudi R; Dai T; Chen S; Fan B; Li H; Zhou Y; Zhou M; Zhu B; Yin C; Li B; Li X
    BMC Cancer; 2019 Jun; 19(1):558. PubMed ID: 31182061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarkers of response to PD-1/PD-L1 inhibition.
    Maleki Vareki S; Garrigós C; Duran I
    Crit Rev Oncol Hematol; 2017 Aug; 116():116-124. PubMed ID: 28693793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade.
    Hirsch L; Zitvogel L; Eggermont A; Marabelle A
    Br J Cancer; 2019 Jan; 120(1):3-5. PubMed ID: 30413824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
    Zhou TC; Sankin AI; Porcelli SA; Perlin DS; Schoenberg MP; Zang X
    Urol Oncol; 2017 Jan; 35(1):14-20. PubMed ID: 27816403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer.
    Baraibar I; Melero I; Ponz-Sarvise M; Castanon E
    Drug Saf; 2019 Feb; 42(2):281-294. PubMed ID: 30649742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy.
    Naidoo J; Wang X; Woo KM; Iyriboz T; Halpenny D; Cunningham J; Chaft JE; Segal NH; Callahan MK; Lesokhin AM; Rosenberg J; Voss MH; Rudin CM; Rizvi H; Hou X; Rodriguez K; Albano M; Gordon RA; Leduc C; Rekhtman N; Harris B; Menzies AM; Guminski AD; Carlino MS; Kong BY; Wolchok JD; Postow MA; Long GV; Hellmann MD
    J Clin Oncol; 2017 Mar; 35(7):709-717. PubMed ID: 27646942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-1 as a potential target in cancer therapy.
    McDermott DF; Atkins MB
    Cancer Med; 2013 Oct; 2(5):662-73. PubMed ID: 24403232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune Checkpoint Blockade in Cancer Immunotherapy: Mechanisms, Clinical Outcomes, and Safety Profiles of PD-1/PD-L1 Inhibitors.
    Yan Y; Zhang L; Zuo Y; Qian H; Liu C
    Arch Immunol Ther Exp (Warsz); 2020 Nov; 68(6):36. PubMed ID: 33185750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Small Molecule Inhibitors of Programmed Cell Death (PD)-1, and its Ligand, PD-L1 in Cancer Immunotherapy: A Review Update of Patent Literature.
    Kopalli SR; Kang TB; Lee KH; Koppula S
    Recent Pat Anticancer Drug Discov; 2019; 14(2):100-112. PubMed ID: 30370857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune Checkpoint Blockade in Breast Cancer Therapy.
    Bu X; Yao Y; Li X
    Adv Exp Med Biol; 2017; 1026():383-402. PubMed ID: 29282694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.